Semaglutide weight loss pills: what the evidence actually shows

What the OASIS 4 trial found, and how to read the numbers

The MHRA's June 2026 approval was built on data from OASIS 4, a phase 3 trial involving 307 adults with obesity or overweight plus at least one weight-related condition, who took daily oral semaglutide alongside lifestyle changes for 64 weeks. Average weight loss reached roughly 13.6% compared with around 2.4% for placebo. Among participants who adhered fully throughout the trial, that figure climbed to about 17%. It matters how you read those two numbers: the 17% is the ceiling for motivated, consistent use; the 13.6% is the more honest population average, and it is the figure cited in the MHRA's approval communications. Both are meaningful. Neither is guaranteed for any individual, biology, starting weight, diet and activity all play a part. The most common side effects in OASIS 4 were gastrointestinal: nausea, loose stools and reflux affected around 74% of people on the active tablet versus 42% on placebo, but the vast majority were mild to moderate and tended to ease as the body adjusted at each dose step.

You can read more detail on how these results compare with the injection in our overview of whether semaglutide pills work for weight loss.

How the tablet differs from the semaglutide injection

The active ingredient is the same GLP-1 receptor agonist used in the weekly Wegovy injection (semaglutide) but the oral version is co-formulated with an absorption enhancer called SNAC, which allows semaglutide to cross the stomach lining rather than be broken down by it. That formulation step is why the tablet comes with a specific administration rule: it must be taken first thing in the morning, on a completely empty stomach, with a small amount of plain water (up to around 120 ml). Then you wait at least 30 minutes before any food, drink (including coffee), or other oral medicines. Miss that window (say, because you took it with a morning cup of tea) and absorption drops significantly. For anyone whose mornings are unpredictable, building a habit before the kettle even goes on tends to work best.

Beyond that routine, the practical differences from the injection are notable. The tablet needs no refrigeration, which makes it far more practical for travel. There are no needles, no injection technique to learn, and no sharps disposal to arrange. For people who are needle-averse or who simply prefer not to self-inject, these are genuinely important factors. Our Wegovy weight loss pill page covers the full comparison in more detail, including what happens if you are already established on the 2.4 mg injection and a prescriber considers switching you.

Who these pills are licensed for, and what a prescriber looks at

The MHRA licence covers adults with a BMI of 30 or above, or those with a BMI between 27 and 29.9 who also have at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or obstructive sleep apnoea. Treatment is meant to run alongside a reduced-calorie diet and increased physical activity. The tablet is not licensed for people under 18, and it is not recommended during pregnancy, whilst breastfeeding, or when trying to conceive.

A BMI figure alone does not open the door. Every prescriber looks at the broader picture: other medicines you take, your medical history, and whether any contraindications apply. Oral semaglutide is a prescription medicine precisely because those individual factors matter. The semaglutide tablets for weight loss page sets out the eligibility criteria in full, and our FAQs cover common questions about the assessment process. It is also worth noting that Rybelsus (another oral semaglutide tablet, in 3 mg, 7 mg and 14 mg strengths) is licensed for type 2 diabetes management, not for weight loss. The two are easily confused by name, but the licensed indications are entirely different. If you have come across references to a 7 mg semaglutide tablet for weight loss, those queries typically relate to Rybelsus, which is prescribed for diabetes, not weight management.

What the NHS situation is right now

At the time of writing, the Wegovy tablet is not available on the NHS. A NICE appraisal would be required before NHS commissioning could follow, and that process typically takes time after a new licence is granted. The injection form of Wegovy has its own NICE recommendation (TA875), but that guidance does not automatically extend to the tablet. Until a separate appraisal concludes, access to semaglutide pills for weight loss in the UK is through private prescription only.

For people who want to explore their options now, the where to buy semaglutide tablets in the UK page explains the legal routes and what to look for in a regulated provider. Our Wegovy pill overview brings together the full clinical picture, including cost context and how the consultation works, and you can see the range of weight loss treatments our prescribers review. If you think this option might suit you, checking your eligibility is the right first step, a prescriber, not an algorithm, reviews every consultation at nume.